Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B

Pharmaceutical Research

Volumn 24, Issue 10, 2007, Pages 1834-1843

  Lu, Dongmei ^a   Garcia Contreras, Lucila ^a   Xu, Ding ^a   Kurtz, Sherry L ^b   Liu, Jian ^a   Braunstein, Miriam ^b   McMurray, David N ^c   Hickey, Anthony J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Aerosol; Ag85B; Macrophages; Microspheres; Mycobacterium tuberculosis

Indexed keywords

BACTERIAL PROTEIN; BCG VACCINE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICROSPHERE; POLYGLACTIN; RECOMBINANT ANTIGEN; RECOMBINANT ANTIGEN 85B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL STRAIN; BCG VACCINATION; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ESCHERICHIA COLI; HUMAN; HUMAN CELL; HYBRIDOMA CELL CULTURE; IMMUNE RESPONSE; IN VITRO STUDY; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MICROENCAPSULATION; MICROPARTICLE ENZYME IMMUNOASSAY; MOLECULAR SIZE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ACYLTRANSFERASES; ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CHEMISTRY, PHARMACEUTICAL; CLONING, MOLECULAR; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; ESCHERICHIA COLI; HUMANS; HYBRIDOMAS; IMMUNITY, CELLULAR; INTERLEUKIN-2; KINETICS; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICROSPHERES; PARTICLE SIZE; POLYGLACTIN 910; RECOMBINANT PROTEINS; TUBERCULOSIS VACCINES;

EID: 34548555768     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9302-8     Document Type: Article

References (61)

1. A. W. Olsen, and P. Andersen. A novel TB vaccine; strategies to combat a complex pathogen. Immuno.l Lett. 85(2):207-211 (2003).
2. L. Brandt, T. Oettinger, A. Holm, et al. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J. Immunol. 157:3527-3533 (1996).
3. I. Rosenkrands, P. B. Rasmussen, M. Carnio, et al. Identification and characterization of a 29KD protein from mycobacterium tuberculosis culture filtrate recognized by mouse memory effecter cells. Infect. Immun. 66:2728-2735 (1998).
4. F. X. Berthet, P. B. Rasmussen, I. Rosenkrands, et al. A mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology. 144:3195-3203 (1998).
5. A. S. Mustafa. Development of new vaccines and diagnostic reagents against tuberculosis. Molec. Immunol. 39:113-119 (2002).
6. T. M. Doherty, A. W. Olsen, L. van Pinxteren, et al. Oral vaccination with subunit vaccines protects animals against aerosol infection with mycobacterium tuberculosis. Infect. Immun. 70:3111-3121 (2002).
7. L. Brandt, Y. A. W. Skeiky, and M. R. Alderson. The protective effect of the mycobacterium bovis BCG vaccine is increased by coadminstration with the mycobacterium tuberculosis 72KD fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect. Immun. 72(11):6622-6632 (2004).
8. H. McShane, R. Brookes, S. C. Gilbert, et al. Enhanced immunogenicity of CD4+ T-Cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Infect. Immun. 69:681-686 (2001).
9. P. F. Barnes, A. B. Bloch, P. T. Davidson, et al. Tubercuslosis in patients with human immunodeficiency virus infection. N. Engl. J. Med. 324:1644-1650 (1991).
10. D. V. Havlir, R. S. Wallis, W. H. Boom, et al. Human immune responses to mycobacterium tuberculosis antigens. Infect. Immun. 59:665-670 (1991).
11. J. T. Belisle, V. D. Vissa, and T. Sievert. Role of the major antigen of mycobacterium tuberculosis in cell wall biogenesis. Science. 276:1420-1422 (1997).
12. D. R. Ronning, V. Vissa, and G. S. Besra. Mycobacterium tuberculosis antigen 85A and 85C structures confirm binding orientation and conserved substrate specificity. J. BiolChem. 279(35):36771-36777 (2004).
13. M. Daffe. The mycobacterial antigen 85 complex-from structure to function and beyond. Trends Microbiol. 8:438-440 (2000).
14. H. G. Wiker, and M. Harboe. The anitgen 85 comlex: a major secretion product of mycobacterium tuberculosis. Microbiol. Rev. 56:648-661 (1992).
15. S. L. Baldwin, C. D. D'Souza, and I. M. Orme. Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. Tuber. Lung Dis. 79:251-259 (1999).
16. O. Denis, A. Tanghe, and K. Palfliet. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect. Immun. 66:1527-1533 (1998).
17. J. B. Ulmer, M. A. Liu, and D. L. Montgomery. Expression and immunogenicity of Mycobacterium tuberculosis antigen 85 by DNA vaccination. Vaccine. 15:792-794 (1997).
18. E. Lozes, K. Huygen, J. Content, et al. Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine. 15:830-833 (1997).
19. M. A. Horwitz, G. Harth, B. J. Dillon, et al. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. U. S. A. 97:13853-13858 (2000).
20. K. Miki, T. Nagata, T. Tanaka, et al. Induction of protective cellular immunity against Mycobacterium tuberculosis by recombinant attenuated self-destructing Listeria monocytogenes strains harboring eukaryotic expression plasmids for antigen 85 complex and MPB/MPT51. Infect. Immun. 72(4):2014-2021 (2004).
21. A. W. Olsen, L. A. H. van Pinxtern, P. B. Rasmussen, et al. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT 6. Infect. Immun. 69(5):2773-2778 (2001).
22. G. Harth, B. Y. Lee, J. Wang, et al. Novel insights into the genetics, biochemistry, and immunocytochemistry of the 30-kilodalton major extracellular protein of Mycobacterium tuberculosis. Infect. Immun. 64:3038-3047 (1996).
23. B. Y. Lee, and W. A. Horwitz. Identification of macrophage and stress-induced protiens of Mycobacteruim tuberculosis. J. Clin. Invest. 96:245-249 (1995).
24. M. A. Horwitz, B. W. Lee, B. J. Dillon, et al. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 92:1530-1534 (1995).
25. K. Salim, V. Haedens, J. Content, et al. Heterologous expression of the mycobacterium tuberculosis gene encoding antigen 85A in Corynebacterium glutamicum. Appl. Envir. Microbiol. 63(11):4392-4400 (1997).
26. J. H. Eldridge, J. K. Staas, J. A. Meulbroek, et al. Biodegradable microspheres as a vaccine delivery system. Molecul. Immunol. 28(3):287-294 (1991).
27. W. Jiang, R. K. Gupta, M. C. Deshpade, et al. Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug. Deliv. Rev. 57:391-410 (2005).
28. H. O. Alpar, S. Somavarapu, K. N. Atuah, et al. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug. Deliv. Rev. 57:411-430 (2005).
29. H. Tamber, P. Johansen, H. Merkle, et al. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug. Deliv. Rev. 57:357-376 (2005).
30. R. Audran, K. Peter, J. Dannull, et al. Encapsulation of peptides in biodegrable microspheres prolongs their MHC class I presentation by dendritic cells and macrphages in vitro. Vaccine. 21:1250-1255 (2003).
31. H. M. Vordermeier, A. G. A. Coombes, P. Jenkins, et al. Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M.tuberculosis 38kDa protein entrapped in biodegrable PLG microspheres. Vaccine. 13:1576-1582 (1995).
32. Y. Men, R. Audran, C. Thomasin, et al. MHC class I- and class II- restricted processing and presentation of microencapsulated antigens. Vaccine. 17:1047-1056 (1999).
33. D. T. O'Hagan, M. Singh, and R. K. Gupta. Poly(lactide-co-glycolide) microspheres for the development of single-dose controlled-release vaccines. Adv. Drug. Deliv. Rev. 32:225-2246 (1998).
34. R. K. Gupta, and G. R. Siber. Adjuvants for human vaccines-current status, problems and future prospects. Vaccine. 13:1263-1276 (1995).
35. A. Raychaudhuri, and K. L. Rock. Fully mobilizing host defense: Building better vaccines. Nat. Biotechnol. 16:1025-1031 (1998).
36. P. K. Gupta and A. J. Hickey. Contemporary approaches in aerosolized drug delivery to the lung. J. Control. Release. 17(2):127-147 (1991).
37. P. Gehr, M. Geiser, and V. ImHof. Surfactant and inhaled particles in the conducting airways: structural, stereological, and biophysical aspects. Microsc. Res. Tech. 26(5):423-436 (1993).
38. P. Bezdicek, and R. G. Crystal. Pulmonary macrophages. 2nd ed. In R. G. Crystal, J. B. West, et al. (eds.), The Lung: Scientific Foundations, Lippincott: Philadelphia, 1997, pp. 859-875.
39. Y. Men, B. Gander, H. P. Merkle, et al. Induction of sustained and elevated immune response to weakly immunogenic synthetic material peptides by encapsulation in biodegrable polymer microspheres. Vaccine. 14:1442-1450 (1996).
40. R. Shahin, M. Leef, J. Eldridge, et al. Adjuvanticity and protective immunity elicited by bordelella pertussis antigens encapsulated in poly(dl-lactide-xo-glycolide) microspheres. Infect. Immun. 63:1195-1200 (1995).
41. D. L. Lakey, R. K. R. Voladri, K. M. Edwards, et al. Enhanced production of recombinant mycobacterium tuberculosis antigens in E coli by replacement of low-usage codons. Infect. Immun. 68(1):233-238 (2000).
42. D. H. Canaday, A. J. Gehring, E. G. Leonard, et al. T-cell hybridomas from HLA-transgenic mice as tools for analysis of human antigen processing. J. Immunol. Methods. 281(1-2):129-142 (2003).
43. A. J. Gehring, R. E. Rojas, D. H. Canaday, et al. The mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and FcgR1 on human macrophages through toll-like receptor 2. Infect Immun. 71(8):4487-4497 (2003).
44. M. F. Powell, L. C. Foster, A. R. Becker, et al. Formulation of vaccine adjuvant muramyldipeptides (MDP). 2. The thermal reactivity and pH of maximum stability of MDP compounds in aqueous solution. Pharm. Res. 5(8):528-532 (1988).
45. G. S. Ritzinger, S. C. Meredith, K. Takayama, et al. The role of surface in the biological activities of trehalose 6,6′-dimycolate. J. Biol. Chem. 256(15):8208-8216 (1981).
46. A. J. Hickey, N. M. Concessio, and M. M. OrtVan. Factors influencing the dispersion of dry powders as aerosols. Pharm. Technol. 18:58-64 (1994).
47. P. H. Bessette, F. Åslund, B. Beckwith, et al. Efficient folding of proteins with multiple disulfide bonds in the Escherichia coli cytoplasm. Proc. Natl. Acad. Sci. U. S. A. 96:13703-13708 (1999).
48. F. U. Hartl and M. Hayer-Hartl. Molecular chaperones in the cytosol: from nacent chain to folded protein. Science. 295:1852-1858 (2002).
49. D. J. Marciani. Vaccien adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today. 8(20):934-943 (2003).
50. H. Takada, S. Yokoyama, and S. Yang. Enhancement of endotoxin activity by muramyl dipeptide. J. Endotoxin Res. 8(5):337-342 (2002).
51. H. Takada and C. Galanos. Enhancement of endotoxin lethality and generation of anaphylactoid reactions by lipopolysaccharides in muramyl-dipeptide-treated mice. Infect. Immun. 55(2):409-413 (1987).
52. B. G. Jones, P. A. Dickinson, M. Gumbleton, et al. Lung surfactant phospholipids inhibit the uptake of respirable microspheres by the alveolar macrophages NR8383. J. Pharm. Pharmacol. 54:1065-1072 (2002).
53. C. Evora, I. Sorino, R. A. Rogers, et al. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Control. Release. 51:143-152 (1998).
54. B. G. Jones, Dickinson, P. A., Gumbleton, M., and Kellaway, I. W. The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages. Inter. J. Pharm. 236:65-79 (2002).
55. K. Sugiyama, S. Mitsuno, and K. Shiraishi. Adsorption of protein on the surface of thermosensitive poly (methyl methacrylate) microspheres modified with the N-(2-Hydroxypropyl) methacrylamide and 2- (Methacryloyloxy) ethyl Phosphorylcholine moieties. J. Polymer. Sci: Part A: Polymer Chem. 35:3349-3357 (1996).
56. T. Basinska. Adsorption studies of human serum albumin, human gama-globulins, and human fibrinogen on the surface of P(S/PGL) microsphere. J. Biomater. Sci. Polymer Edn. 12(12):1359-1371 (2001).
57. C. Witt and T. Kissel. Morphological characterization of microspheres, films and implants prepared from poly(lactide-co-glycolide) and ABA triblock copolymers: is the erosion controlled by degradation, swelling or diffusion? Eur. J. Pharm. Biopharm. 51(3):171-181 (2001).
58. L. Vidard, M. Kovacsovics-Bankowski, S.-K. Kraeft, et al. Analysis of MHC class II presentation of particulate antigens by B lymphocytes. J. Immunol. 156:2809-2818 (1996).
59. A. J. Sant, F. A. Chaves, S. A. Jenks, et al. The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes. Immunol. Rev. 207:261-278 (2005).
60. M. T. Valle, A. M. Megiovanni, A. Merlo, et al. Epitope focus, clonal composition and Th1 phenotype of the human CD4 response to the secretory mycobacterial antigen Ag85. Clin. Exp. Immunol. 123(2):226-232 (2001).
61. M. Torres, L. Ramachandra, R. E. Rojas, et al. Role of phagosomes and major histocompatibility complex class II (MHC-II) compartment in MHC-II antigen processing of Mycobacterium tuberculosis in human macrophages. Infect. Immun. 74(3):1621-1630 (2006).